Track topics on Twitter Track topics that are important to you
InflaRx has announced that its shares will cost $15 when they’re launched for the company’s IPO, which could bring in over $100M for the biotech. InflaRx focuses on developing monoclonal antibodies targeted towards the complement system to treat potentially fatal ...
This awesome article German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)NEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...